BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. BMRN has ...

By Maggie Fick LONDON (Reuters) -Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on ...

Correspondence seen by The Irish Times shows several big pharma companies, such as Pfizer, MSD, Novo Nordisk and AstraZeneca, ...

Pharmaceutical companies are currently granted at least eight years’ “protection” over their data from research and clinical ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

The success of Latin America's regional trade ambitions will depend heavily on adoption of tailored logistics strategies that ...

A groundbreaking court ruling in South Africa has upheld Eurolab's right to produce affordable cancer treatment, invalidating a University of California patent claim. This landmark decision ensures ...

Shares in WuXi AppTec rose sharply after the Chinese biotechnology company proposed a special dividend and share buyback following weaker annual results. The company's shares in Hong Kong climbed as ...

Bay Area life sciences conference will cover the factors behind stabilizing supply and demand for lab space, biotech growth, ...

It’s a tough job analysing share prices and company performances in the middle of a sharp share market downturn, but ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...